| Select | Gene | Cds | Cds_length | GC_content | Pep | Pep_length |
|---|---|---|---|---|---|---|
| Lal22g0493 | ATGGATGTGAAAATGAAAAGCAGGGGAATAGGATTGAGCTTTTTTGTGTTTAACTTTTTTGTATTTTCTTCTATTTTGCCACTCTCTTTCTCAGCTGCCAATCAGCCTCGTAGCTTCAAAAAACCTGATCATCAATTTGGCTCCTCAGCTGTTTTCCCAGTTCAAGGAAATGTATACCCTCTTGGGCATTACACAGTGTCCCTCAACATGGGCTATCCTCCTAAACTTTTTGACCTTGACATTGACTCAGGTAGTGACCTCACCTGGGTTCAGTGTGATGCACCATGTAAAGGTTGCACCAAGCCTAATGATCAACTTTATAAACCCAAGAACAACCTTGTGCGATGTGTGGATCGGTTGTGTGCTGAAGTGCAATTAACAACAGACCAGCATTGTGCTACTCCAGATGATCAATGTGACTATGAGGTTGAGTATGCAGACAATGGATCATCTTTGGGTGTGCTAGTCCAAGACTATGTTCCTCTTCAATTCACCAATGGCTCTGTGGTACGGCCTAGGATAGCCTTCGGGTGTGGATATGATCAAAAGTTTTCTGGTTCTACCTCCCCGCCTTCTACAGCAGGGGTTCTTGGTCTTGGCAGTGGCAGTGCAAGCATTTTGTCCCAGCTTCATTCTCTCGGTCTGATACGCAATGTAGTTGGCCACTGCTTAAGTGGGCGAGGAGGAGGGTTTTTATTCTTCGGAGATGATCTCATTCCCTCATCTGGAATTGTTTGGACACCCATGTTACCTGACTCCTCTGAAAAACACTACAGTGCAGGACCAGCTGAATTGTTTTTCAATGGAAAAACTACTGCTGTTAAGGGTCTCGAACTTATCTTTGATAGTGGGAGTTCTTACACATACTTCAACTCCCAAGCTTATCAAGCCATTGTTGATCTGGTATCTAATGCTTTGAAGGGAAAACAGTTGAAAAGAGCAACCGAGGATCCATCACTTCCAGTTTGTTGGAAGGGTGCAAAGTCTTTCAAATCATTGAGTGATGTCACAAACTATTTTAAGCCCCTAGCTTTGAGCTTCACAAAAATGAAGAATGTGAAGATGCAAATACCACCAGAAGCTTATCTAATTGTCACGAAATATGGCAATGTCTGCTTGGGGATTCTAGATGGCACTGAAGTAGGACTAGAAAATCTTAACATAATAGGAGATATCTCTTTACAAGACAAAATGGTGATTTACGACAATGAGAAACAGCAGATTGGATGGGTTTCTACCAATTGTGATAGGCTTCCCAAGTCATAA | 1266 | 0.425 | MDVKMKSRGIGLSFFVFNFFVFSSILPLSFSAANQPRSFKKPDHQFGSSAVFPVQGNVYPLGHYTVSLNMGYPPKLFDLDIDSGSDLTWVQCDAPCKGCTKPNDQLYKPKNNLVRCVDRLCAEVQLTTDQHCATPDDQCDYEVEYADNGSSLGVLVQDYVPLQFTNGSVVRPRIAFGCGYDQKFSGSTSPPSTAGVLGLGSGSASILSQLHSLGLIRNVVGHCLSGRGGGFLFFGDDLIPSSGIVWTPMLPDSSEKHYSAGPAELFFNGKTTAVKGLELIFDSGSSYTYFNSQAYQAIVDLVSNALKGKQLKRATEDPSLPVCWKGAKSFKSLSDVTNYFKPLALSFTKMKNVKMQIPPEAYLIVTKYGNVCLGILDGTEVGLENLNIIGDISLQDKMVIYDNEKQQIGWVSTNCDRLPKS | 421 |
| Select | Seq ID | Length | Analysis | Description | Start | End | IPR | GO |
|---|---|---|---|---|---|---|---|---|
| Lal22g0493 | 421 | Pfam | Xylanase inhibitor N-terminal | 64 | 236 | IPR032861 | - | |
| Lal22g0493 | 421 | Gene3D | Acid Proteases | 237 | 418 | IPR021109 | - | |
| Lal22g0493 | 421 | PANTHER | EUKARYOTIC ASPARTYL PROTEASE FAMILY PROTEIN | 4 | 418 | - | - | |
| Lal22g0493 | 421 | PRINTS | Pepsin (A1) aspartic protease family signature | 70 | 90 | IPR001461 | GO:0004190|GO:0006508 | |
| Lal22g0493 | 421 | PRINTS | Pepsin (A1) aspartic protease family signature | 279 | 290 | IPR001461 | GO:0004190|GO:0006508 | |
| Lal22g0493 | 421 | PRINTS | Pepsin (A1) aspartic protease family signature | 387 | 402 | IPR001461 | GO:0004190|GO:0006508 | |
| Lal22g0493 | 421 | ProSiteProfiles | Peptidase family A1 domain profile. | 64 | 411 | IPR033121 | - | |
| Lal22g0493 | 421 | Gene3D | Acid Proteases | 40 | 236 | IPR021109 | - | |
| Lal22g0493 | 421 | ProSitePatterns | Eukaryotic and viral aspartyl proteases active site. | 279 | 290 | IPR001969 | GO:0004190|GO:0006508 | |
| Lal22g0493 | 421 | PANTHER | ASPARTYL PROTEASES | 4 | 418 | IPR001461 | GO:0004190|GO:0006508 | |
| Lal22g0493 | 421 | SUPERFAMILY | Acid proteases | 56 | 418 | IPR021109 | - | |
| Lal22g0493 | 421 | Pfam | Xylanase inhibitor C-terminal | 278 | 410 | IPR032799 | - |
| Select | Gene | Chromosome | Start | End | Duplicated_type |
|---|---|---|---|---|---|
| Lal22g0493 | Lal-Chr22 | 3253396 | 3262242 | Dispersed/Wgd |
| Select | Gene | Gene_start | Gene_end | Function | Ath_gene | Identity(%) | E-value | Score |
|---|---|---|---|---|---|---|---|---|
| Lal22g0493 | 25 | 421 | Miscellaneous Gene Families | AT1G44130 | 58.040 | 8.32e-174 | 490 |
| Select | Query | KO | Definition | Second KO | KEGG Genes ID | GHOSTX Score |
|---|---|---|---|---|---|---|
| Lal22g0493 | - | - | aprc:113846122 | 694.501 |
| Select | Gene_1 | Chr_1 | Start_1 | End_1 | Gene_2 | Chr_2 | Start_2 | End_2 | Event_name |
|---|---|---|---|---|---|---|---|---|---|
| Lal22g0493 | 22 | 3253396 | 3262242 | Lal22g0493 | 22 | 3253396 | 3262242 | ECH |